-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Orthopoxvirus
- Others
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Virus Protease
- Antiviral intermediates
Imiquimod maleate
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/896106-16-4.gif)
| Category | SARS-CoV |
| CAS | 896106-16-4 |
| Description | Imiquimod maleate is an immune response modifier. It acts as a toll-like receptor 7 agonist. It is commonly used topically to treat warts on the skin of the genital and anal areas. It is also used to treat certain diseases of the skin, including skin cancers, such as basal cell carcinoma, Bowen's disease, superficial squamous cell carcinoma, some superficial malignant melanomas, and actinic keratosis. It can lead to the activation of Langerhans cells, which subsequently migrate to local lymph nodes to activate the adaptive immune system when applied to skin. |
Product Information
| Synonyms | R 837 maleate; R837 maleate; R-837 maleate |
| IUPAC Name | (Z)-but-2-enedioic acid;1-(2-methylpropyl)imidazo[4,5-c]quinolin-4-amine |
| Molecular Weight | 356.38 |
| Molecular Formula | C18H20N4O4 |
| Canonical SMILES | NC1=NC2=CC=CC=C2C3=C1N=CN3CC(C)C.O=C(O)/C=C\C(O)=O |
| InChI | InChI=1S/C14H16N4.C4H4O4/c1-9(2)7-18-8-16-12-13(18)10-5-3-4-6-11(10)17-14(12)15;5-3(6)1-2-4(7)8/h3-6,8-9H,7H2,1-2H3,(H2,15,17);1-2H,(H,5,6)(H,7,8)/b;2-1- |
| InChIKey | KYQFLNAOJRNEDV-BTJKTKAUSA-N |
| Purity | >98% |
| Solubility | 10 mM in DMSO |
| Appearance | Solid powder |
| Application | Imiquimod maleat is commonly used topically to treat warts on the skin of the genital and anal areas. It is also used to treat certain diseases of the skin, including skin cancers, such as basal cell carcinoma, Bowen's disease, superficial squamous cell carcinoma, some superficial malignant melanomas, and actinic keratosis. |
| Shelf Life | 2 month in rt, long time |
| Storage | -20°C Freezer |
| Complexity | 413 |
| Exact Mass | 356.14845513 |
| In Vitro | TLR7, HSV-1 |
| In Vivo | In animal models, imiquimod stimulates the innate immune response by increasing NK cell activity, activating macrophages to secretecytokines and nitric oxide, and inducing proliferation and differentiation of B lymphocytes. Imiquimod stimulates the innate immune response through induction, synthesis, and release of cytokines, including interferon-a (IFN-α), interleukin (IL)-6, and tumour necrosis factor (TNF)-α. |
| Target | Toll-like Receptor (TLR); Autophagy; SARS-CoV; HSV |
